浸潤性膀胱癌に対する術前抗癌化学療法としてのGC療法とMVAC療法の比較

HANDLE Web Site オープンアクセス

書誌事項

タイトル別名
  • Relative Efficacy of Neoadjuvant Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Adriamycin, and Cisplatin in the Management for Muscle-Invasive Bladder Cancer
  • シンジュンセイ ボウコウガン ニ タイスル ジュツゼン コウガン カガク リョウホウ ト シテ ノ GC リョウホウ ト MVAC リョウホウ ノ ヒカク

この論文をさがす

説明

Systemic cisplatin-based chemotherapy regimens are the gold standard in advanced bladder cancer. Gemcitabine plus cisplatin (GC) therapy has often been used, although there is no significant evidence that it is better than methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) therapy in neoadjuvant chemotherapy. We retrospectively evaluated the relative efficacy of the two chemotherapeutic regimens in the management of muscle-invasive bladder cancer on patients who had had radical cystectomy for clinical stage T2-T4, N and, M0 bladder cancer. Fourteen patients (24.1%) and 44 (75.9%) patients were treated with GC and MVAC therapy, respectively. GC therapy was significantly more effective than MVAC therapy in pathological down-staging (to pT0) rate. On multivariate analysis, the choice of regimen (MVAC) was an independent predictor of the presence of residual cancer after a neoadjuvant chemotherapy. The clinical response to neoadjuvant GC therapy was superior to that to neoadjuvant MVAC therapy. Moreover, GC therapy was associated with less non-hematologic toxicity than MVAC therapy, especially with respect to the occurrence of nausea.

収録刊行物

  • 泌尿器科紀要

    泌尿器科紀要 59 (5), 277-281, 2013-05

    泌尿器科紀要刊行会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ